Core Viewpoint - The article discusses the privatization plan of Kangji Medical (9997.HK) initiated by a consortium led by TPG and other investors, highlighting the potential benefits for shareholders amidst market volatility and geopolitical risks [2][4]. Group 1: Privatization Details - On October 13, Kangji Medical announced the publication of a privatization proposal document, marking a critical phase in the transaction [2]. - The privatization is led by a consortium including TPG's funds, NewQuest, Qatar's sovereign fund Al-Rayyan Holding, and the founding entity, with a cash buyout price of HKD 9.25 per share, valuing the company at approximately USD 1.4 billion (around HKD 11.2 billion) [4]. - The independent board committee, after consulting with independent financial advisors, deemed the privatization plan fair and reasonable, recommending shareholders to vote in favor [4]. Group 2: Timeline and Process - A court meeting and a special shareholder meeting are scheduled for November 10, with results expected by 7:00 PM the same day. If approved, subsequent procedures will include a Cayman court hearing, capital reduction, share cancellation, and cash payment, anticipated to take effect by December 5, with formal delisting on December 9 [4]. - Kangji Medical, established in 2004 and listed on the Hong Kong Stock Exchange in 2020, is the largest minimally invasive surgical instrument and consumables platform in China, serving over 3,500 hospitals, including more than 1,000 top-tier hospitals, with operations in over 90 countries and regions [4]. Group 3: Market Context - The company has faced low average turnover rates over the past two years, leading to liquidity challenges. The privatization is seen as a way to attract long-term strategic investments rather than focusing on short-term performance pressures [5]. - As of October 13, Kangji Medical's stock price was HKD 8.9, with a market capitalization of HKD 10.7 billion [6].

Core Viewpoint - The leading minimally invasive medical device company, Kangji Medical Holdings Limited, is planning to go private through an agreement with Knight Bidco Limited, which will result in the company's delisting from the Hong Kong Stock Exchange [2][4]. Group 1: Privatization Details - The consortium involved in the offer includes notable entities such as the founders, TPG, NewQuest V Fund, and Al-Rayyan Holding, which is fully owned by Qatar Investment Authority [4][9]. - The proposed cancellation price for the shares is set at HKD 9.25 per share, valuing the company at approximately USD 1.4 billion (around HKD 10.99 billion), representing a premium of about 21.7% over the closing price on June 30, 2025 [4][7]. - As of August 13, 2023, Kangji Medical's stock price was HKD 8.50, reflecting a year-to-date increase of 40.28%, although it remains significantly below the IPO price of HKD 13.88 set in June 2020 [4][7]. Group 2: Market Conditions and Company Strategy - The company has faced persistent pressure on its stock price and long-term liquidity issues, limiting its ability to raise funds from the market [7]. - The need to maintain its listing incurs administrative and compliance costs, which, coupled with increased competition and industry uncertainties, has led the company to consider significant investments for sustainable growth [7]. - The necessity of maintaining a public listing has diminished, prompting the decision to pursue privatization [7]. Group 3: Shareholder Dynamics - The founders, Zhong Ming and Shen Tu Yingguang, currently control 52.98% of Kangji Medical and will retain a 40% stake in the ultimate holding company post-privatization, ensuring they remain the largest shareholders [10]. - The acceptance of the privatization proposal by minority shareholders remains uncertain and will depend on future developments [11].